|
|
Blood, 15 April 2006, Vol. 107, No. 8, pp. 3321-3329.
Prepublished online as a Blood First Edition Paper on December 27, 2005; DOI 10.1182/blood-2005-06-2445.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function
Alfonso Catalano,
Paola Caprari,
Simona Moretti,
Monica Faronato,
Luca Tamagnone, and
Antonio Procopio
From the Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona, Italy; the Center of Cytology, Italian National Research Centers on Aging (INRCA-IRCCS), Ancona, Italy; the Neural Development Group, Mouse Cancer Genetics Program, National Cancer Institute, Frederick, MD; and the Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy.
An important aspect of tumor progression is the ability of cancer cells to escape detection and clearance by the immune system. Recent studies suggest that several tumors express soluble factors interfering with the immune response. Here, we show that semaphorin-3A (Sema-3A), a secreted member of the semaphorin family involved in axonal guidance, organogenesis, and angiogenesis, is highly expressed in several tumor cells. Conditioned media of Sema-3A-transfected COS-7 cells or human recombinant Sema-3A inhibited primary human T-cell proliferation and cytokines production under anti-CD3 plus anti-CD28 stimulating conditions. Sema-3A also inhibited the activation of nonspecific cytotoxic activity in mixed lymphocyte culture (MLC), as measured against K-562 cells. In contrast, suppression of Sema-3A in tumor cells with a small interfering RNA (siRNA) augmented T-cell activation. The inhibitory effect of Sema-3A in T cells is mediated by blockade of Ras/mitogen-activated protein kinase (MAPK) signaling pathway. The presence of Sema-3A increased the activation of the Ras family small GTPase Rap1 and introduction of the dominant-negative mutant of Rap1 (Rap1N17) blunted the immunoinhibitory effects of Sema-3A. These results suggest that Sema-3A inhibits primary T-cell activation and imply that it can contribute to the T-cell dysfunction in the tumor microenvironment.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Gaur, D. R. Bielenberg, S. Samuel, D. Bose, Y. Zhou, M. J. Gray, N. A. Dallas, F. Fan, L. Xia, J. Lu, et al.
Role of Class 3 Semaphorins and Their Receptors in Tumor Growth and Angiogenesis
Clin. Cancer Res.,
November 15, 2009;
15(22):
6763 - 6770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Capparuccia and L. Tamagnone
Semaphorin signaling in cancer cells and in cells of the tumor microenvironment - two sides of a coin
J. Cell Sci.,
June 1, 2009;
122(11):
1723 - 1736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Catalano, R. Lazzarini, S. Di Nuzzo, S. Orciari, and A. Procopio
The Plexin-A1 Receptor Activates Vascular Endothelial Growth Factor-Receptor 2 and Nuclear Factor-{kappa}B to Mediate Survival and Anchorage-Independent Growth of Malignant Mesothelioma Cells
Cancer Res.,
February 15, 2009;
69(4):
1485 - 1493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Lazzarini, S. Moretti, S. Orecchia, P.-G. Betta, A. Procopio, and A. Catalano
Enhanced Antitumor Therapy by Inhibition of p21waf1 in Human Malignant Mesothelioma
Clin. Cancer Res.,
August 15, 2008;
14(16):
5099 - 5107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yamamoto, K. Suzuki, T. Okuno, T. Ogata, N. Takegahara, H. Takamatsu, M. Mizui, M. Taniguchi, A. Chedotal, F. Suto, et al.
Plexin-A4 negatively regulates T lymphocyte responses
Int. Immunol.,
March 1, 2008;
20(3):
413 - 420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Moretti, A. Procopio, R. Lazzarini, M. R. Rippo, R. Testa, M. Marra, L. Tamagnone, and A. Catalano
Semaphorin3A signaling controls Fas (CD95)-mediated apoptosis by promoting Fas translocation into lipid rafts
Blood,
February 15, 2008;
111(4):
2290 - 2299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
